Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-FAB-CD3 ScFv-Fc
- Development stage
- Preclinical
- Lead developer
- ProMab Biotechnologies
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
BCMA-FAB-CD3 ScFv-Fc is a humanized bispecific antibody candidate developed by ProMab Biotechnologies for the treatment of multiple myeloma. It features a unique "triple chain" architecture consisting of a Fab fragment targeting B-cell maturation antigen (BCMA), a single-chain variable fragment (ScFv) targeting CD3, and an Fc region to enhance stability and pharmacokinetics. The molecule acts as a T-cell engager, simultaneously binding to BCMA on malignant plasma cells and the CD3 complex on T cells, thereby inducing T-cell activation and directed cytotoxicity against the tumor cells. Preclinical data presented at AACR 2022 demonstrated high binding affinity (Kd ~0.3 nM) and potent anti-tumor activity in MM1S xenograft mouse models.
- Other names
- triple chain BCMA-FAB-CD3 ScFv-FchBCMA-CD3 bispecific antibodyhBCMA-CD-3 bispecific antibodyhBCMA-CD 3 bispecific antibody
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on BCMA-FAB-CD3 ScFv-Fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-FAB-CD3 ScFv-Fc.